Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial
- 168 Downloads
Existing nicotine replacement therapies (NRT) improve the chances of smoking cessation but are limited by either relatively slow nicotine absorption rates or unpleasant side effects, leaving scope for the development of more effective and acceptable products.
This study aimed to test the acceptability and effectiveness for withdrawal symptom relief of a novel nicotine delivery device, the ‘Nicotine Cannon’ (NC), compared with three existing, equivalent products: the nicotine lozenge, mini-lozenge and nicotine inhalator.
A repeated-measures crossover trial where participants were randomised to one of two conditions (1- or 10-h abstinence) and in each condition to one of 24 possible sequence permutations to test each product for 10 min was carried out. Standard sociodemographic and smoking characteristics were assessed as well as withdrawal and NRT use symptoms before, during and after NRT use and product satisfaction after use.
The results were similar across both durations of abstinence. The NC was significantly more effective than the inhalator in reducing withdrawal symptoms (F(3, 196) = 3.5, p = 0.015) and together with the mini-lozenge performed better than other NRT in alleviating urges to smoke (F(3, 563) = 9.6, p < 0.001) and desire for cigarettes within 10 min of use (F(3, 727) = 26.1, p < 0.001). The NC induced fewer adverse side effects than other NRT and was judged to be more enjoyable (F(3, 87) = 13.56, p < 0.001) and satisfying to use (F(3, 92) = 12.35, p < 0.001).
The ‘Nicotine Cannon’ is at least as effective as equivalent NRT in reducing withdrawal symptoms and more acceptable to users, suggesting that it would be a useful addition to existing NRT. The acceptability profile could make it particularly useful as a ‘harm reduction’ tool.
KeywordsNicotine replacement therapy Withdrawal symptoms Acceptability Smoking cessation Novel treatment
- Beard E, McNeill A, Aveyard P, Fidler J, Michie S, West R (2011) Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction 106(1):197–204Google Scholar
- McEwen A, West R, Gaiger M (2008) Nicotine absorption from seven current nicotine replacement products and a new wide-bore nicotine delivery device. J Smoking Cessation 3:117–123Google Scholar
- MHRA (2010) MHRA Public Assessment Report: the use of nicotine replacement therapy to reduce harm in smokers. Medicine and Healthcare Products Regulatory Agency, LondonGoogle Scholar
- Royal College of Physicians (2000) Nicotine addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. Royal College of Physicians of London, LondonGoogle Scholar
- Royal College of Physicians (2007) Harm reduction in nicotine addiction: helping people who can't quit. Royal College of Physicians of London, LondonGoogle Scholar
- Stead LF, Perera R, Bullen C, Mant D, Lancaster T (2008) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev CD000146Google Scholar
- West R, Shiffman S (2007) Fast facts: smoking cessation. Health, OxfordGoogle Scholar
- WHO (1998) Action for tobacco control. In: Guideline for controlling and monitoring the tobacco epidemic. World Health Organization, GenevaGoogle Scholar